HALO logo
halo search icon
Bicara Therapeutics Inc.
Bicara Therapeutics Inc.
BCAX · NAS

Bicara Therapeutics Inc.

US$20.43

Price Arrow0.40 (2.00%)
20/05/2026 04:00:01 PM
All-CompaniesAll-ConsensusHALO All
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Bicara Therapeutics Inc. Overview

BCAX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About BCAX

icon

Website

Bicara Therapeutics Inc.

icon

Telephone

1.617.468.4219

icon

Address

Suite 703, 116 Huntington Avenue, Boston, MA 02116

Description

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

BCAX Price Chart

Key Stats

Market Cap

US$1.32B

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 7.8 - 24.25

Trade Value (12mth)

US$2,367,937.00

1 week

-0.99%

1 month

-13.33%

YTD

22.28%

1 year

37.29%

All time high

28.09

Key Fundamentals

EPS 3 yr Growth

262.70%

EBITDA Margin

0.00%

Operating Cashflow

-$107m

Free Cash Flow Return

-23.90%

ROIC

-30.90%

Interest Coverage

0.00

Quick Ratio

14.60

Other Data

Shares Outstanding (Fully Diluted)

61m

HALO Sector

Healthcare

Next Company Report Date

01-Apr-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

BCAX Announcements

Latest Announcements

DateAnnouncements
12 May 26
12 May 26
11 May 26
11 May 26
08 April 26

BCAX Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-0.96-1.25-2.52locklocklock
EPS (Fully Diluted)
$locklocklocklock-0.96-1.25-2.52locklocklock
Growth
%locklocklocklock-37.3-30.7-102locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Bicara Therapeutics Inc. (BCAX:NAS)?
Halo FAQ
The current share price of Bicara Therapeutics Inc. (BCAX:NAS) is USD$20.43.
What is the 52-week high share price for Bicara Therapeutics Inc. (BCAX:NAS)?
Halo FAQ
The 52-week high share price for Bicara Therapeutics Inc. (BCAX:NAS) is USD$24.25.
What is the 52-week low share price for Bicara Therapeutics Inc. (BCAX:NAS)?
Halo FAQ
The 52-week low share price for Bicara Therapeutics Inc. (BCAX:NAS) is USD$7.80.
What is the dividend yield for Bicara Therapeutics Inc. (BCAX:NAS)?
Halo FAQ
Bicara Therapeutics Inc. (BCAX:NAS) does not pay a dividend.
What was Bicara Therapeutics Inc. (BCAX:NAS) last dividend payment?
Halo FAQ
Bicara Therapeutics Inc. (BCAX:NAS) does not pay a dividend.
What is the franking level for Bicara Therapeutics Inc. (BCAX:NAS)?
Halo FAQ
Bicara Therapeutics Inc. (BCAX:NAS) has a franking level of 0.00%.
In which sector is Bicara Therapeutics Inc. (BCAX:NAS) classified?
Halo FAQ
Bicara Therapeutics Inc. (BCAX:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.